<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04051892</url>
  </required_header>
  <id_info>
    <org_study_id>CLN003_0100</org_study_id>
    <nct_id>NCT04051892</nct_id>
  </id_info>
  <brief_title>Multicenter Study Evaluating the FixNip™ NRI Safety and Performance</brief_title>
  <official_title>A Prospective, Open Label, Single Arm, Multicenter Study Evaluating the FixNip™ NRI Safety and Performance in Female Patients Seeking Reconstructive Surgery of the Nipple.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FixNip Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FixNip Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, Open Label, Single arm, Multicenter study Evaluating the FixNip™ NRI Safety&#xD;
      and Performance in Female Patients Seeking Reconstructive Surgery of the Nipple.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Prospective, Open label, Single arm, Multicenter Study enrolling female patients&#xD;
      with a history of breast cancer following breast conservation surgery or mastectomy with&#xD;
      breast reconstruction, seeking reconstruction of the breast nipple and areola complex.&#xD;
&#xD;
      The study is designed to evaluate the long-term safety and performance of the FixNip NRI in&#xD;
      patients undergoing nipple reconstruction procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 6, 2020</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The sample size will be 21 women with unilateral replacement (Cohort 1) and another 21 women with bilateral replacement (Cohort 2). A total of 23 patients per cohort will be enrolled to account for up to 9% losses for reasons other than safety or effectiveness.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse event</measure>
    <time_frame>12 months</time_frame>
    <description>Frequency and severity of Adverse Event . All adverse events occurring during the study will be reported</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nipple Projection</measure>
    <time_frame>12 months</time_frame>
    <description>Nipple projection in millimeter (mm)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Satisfaction Evaluation</measure>
    <time_frame>12 months</time_frame>
    <description>Rate of Patient satisfaction questionnaire</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Reconstruction of the Breast Nipple and Areola Complex</condition>
  <arm_group>
    <arm_group_label>Implantation of FixNip™ NRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Female Patients Seeking Reconstructive Surgery of the Nipple</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FixNip™ NRI</intervention_name>
    <description>The FixNip™ NRI is an implantable hypodermic, silicone implant specially designed for nipple areola definition</description>
    <arm_group_label>Implantation of FixNip™ NRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women between the ages of 22-70 years.&#xD;
&#xD;
          -  Patients of childbearing potential must agree to use methods of contraception and have&#xD;
             negative pregnancy test at screening. Effective methods of contraception must be used&#xD;
             throughout the study.&#xD;
&#xD;
          -  History of breast cancer post mastectomy with breast implant or partial mastectomy&#xD;
             (lumpectomy) of the central segment of the breast seeking reconstruction of the nipple&#xD;
             and/or areola complex.&#xD;
&#xD;
          -  At least 3 months post breast reconstruction surgery.&#xD;
&#xD;
          -  Baker scale grade I or II capsular contracture.&#xD;
&#xD;
          -  No evidence of any systemic or chronic disease that might influence wound healing and&#xD;
             infection rate.&#xD;
&#xD;
          -  Event free post breast and/or nipple reconstruction procedure, i.e. no skin infections&#xD;
             or related infections that mandated antibiotic therapy, no wound dehiscence or any&#xD;
             other related medical complications.&#xD;
&#xD;
          -  Pinch test of intended nipple location on affected breast of at least 15 mm.&#xD;
&#xD;
          -  Patient is willing to postpone tattooing until the end of follow-up period.&#xD;
&#xD;
          -  Patient is willing and able to give their written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active malignant disease.&#xD;
&#xD;
          -  Subject has a chronic disease or any medical status that, according to surgeon&#xD;
             discretion, prohibits from inclusion in the study i.e. diabetes.&#xD;
&#xD;
          -  History of tendency to produce hypertrophic scars or keloids.&#xD;
&#xD;
          -  Current use of any medications that can interfere with wound healing, impair the&#xD;
             immune system functionality, or impair blood clotting mechanisms.&#xD;
&#xD;
          -  Active infection within the last 30 days.&#xD;
&#xD;
          -  Pregnant or nursing women.&#xD;
&#xD;
          -  Connective tissue disease.&#xD;
&#xD;
          -  'Lupus disease' defined as Systemic Lupus Erythematous or Discoid Lupus, or&#xD;
             scleroderma defined as Progressive Systemic Sclerosis per history.&#xD;
&#xD;
          -  Chronically treated with steroids or steroid therapy in a 3month period before&#xD;
             surgery.&#xD;
&#xD;
          -  Demonstrate psychological characteristics, which, in the opinion of the Investigator&#xD;
             and/or consulting physician(s) are incompatible with the risks, involved with the&#xD;
             surgical procedure, prosthesis and compliance with follow-up recommendations.&#xD;
&#xD;
          -  Past or current capsular contracture defined as Baker III or IV.&#xD;
&#xD;
          -  Participating in any other investigational study for either drug or device which can&#xD;
             influence collection of valid data under this study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jasmine Shoam, SC</last_name>
    <phone>972-37644015</phone>
    <email>jasmines@assuta.co.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assuta Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jasmin Shoam</last_name>
      <phone>972-37644015</phone>
      <email>jasmines@assuta.co.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 8, 2019</study_first_submitted>
  <study_first_submitted_qc>August 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2019</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

